CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imagingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03212170
NCT03212170Phase 2Completed
CompareCT.gov

[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

University of Wisconsin, Madison·interventional·Posted Jul 11, 2017·Updated Jan 2, 2026

In Brief

A Phase 2 clinical trial evaluating [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging for Invasive Breast Cancer. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Breast Cancer
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 11, 2017
Enrollment StartDec 13, 2017
Primary CompletionNov 14, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 9.0 years ago

Interventions

[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imagingdrug

18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer